Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has earned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $192.07.

Several research firms recently weighed in on ASND. Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen cut their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after buying an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the period. Finally, Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the third quarter worth approximately $60,000.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of ASND opened at $134.43 on Thursday. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The firm’s 50-day moving average price is $132.30 and its 200-day moving average price is $133.59. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of -16.64 and a beta of 0.65.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.